Search

1 to 10 of 248
Sort by

Library Entry
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article suggesting that IL-1α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs. Authors: Madelyn...


Library Entry
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article investigating whether HHLA2, a newly identified B7 family immune checkpoint for T cells, could be a therapeutic target next to PD-L1 in ICC. Author: Chu-Yu Jing , Yi-Peng Fu , Yong Yi , Mei-Xia Zhang , ...


Library Entry
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which the levels of 3 different B7 family ligands PD-L1, B7-H3, B7-H4 and major tumor infiltrating lymphocyte (TIL) subsets in 90 SCLC samples represented in tissue microarray format were measured using...


Library Entry
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article investigating the role of melanoma-associated antibodies as predictive markers for CI therapy Authors: Mirjam Fässler , Stefan Diem , Joanna Mangana , Omar Hasan Ali , Fiamma Berner , David Bomze , ...


Library Entry
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article finding that HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent...



Library Entry
Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article presenting observations which support local PD-(L)1 blockade to interrupt loco-regional immune suppression in CxCa and control metastatic spread to TDLN. Additionally presenting data which identified CD8 + FoxP3 +...


Library Entry
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article which studied two patients with unexpected responses to checkpoint blockade monotherapy: a patient with PD-L1-negative and low mutational burden NSCLC and one with mismatch repair proficient colorectal cancer (CRC...


Library Entry
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which tumor specimens from 120 NSCLC patients from 10 institutions were evaluated for PD-L1 expression by immunohistochemistry, and global proliferative profile by targeted RNA-seq. The article concludes that...


Library Entry
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article seeking to improve Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC). Results show some features were associated with favorable response to nivolumab for AGC....